Literature DB >> 21645195

Increase of body weight during the first year of intensive insulin treatment in type 2 diabetes: systematic review and meta-analysis.

A E Pontiroli1, L Miele, A Morabito.   

Abstract

AIM: This systematic review and meta-analysis was to evaluate the body weight increase and its clinical correlates, through direct weighted regressions, as well as the effect of different insulin regimens and insulin analogues, through meta-analysis.
METHODS: Appropriate methodology according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement was adhered to. Forty-six randomized studies, published as full papers, reporting the effect of insulin treatment on change in body weight were identified, and used to identify predictors of weight change; studies were included in a meta-analysis to study the effect of different insulin regimens or insulin analogues on weight change.
RESULTS: Intensity of treatment [aim of study (fasting blood glucose, mg/dl), dose of insulin, final HbA1c, change of HbA1c and frequency of hypoglycaemia] was significantly associated with body weight increase, with small differences between basal versus twice-a-day and prandial regimen. At meta-analysis, body weight increase was lower with basal regimen than with twice-a-day regimen and than with a prandial regimen. Within all regimens, body weight increase was lower with detemir than with NPH, with no difference between glargine and NPH; only two studies directly compared detemir and glargine, indicating lower weight gain with the former insulin. Within twice-a-day regimens and within prandial regimens, comparison was between newer analogues and older drugs, with no significant difference in body weight increase.
CONCLUSION: Body weight increase during the first year of insulin treatment is associated with the intensity of treatment; body weight increase also depends on the insulin regimen applied.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21645195     DOI: 10.1111/j.1463-1326.2011.01433.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  38 in total

1.  Is FTO a type 2 diabetes susceptibility gene?

Authors:  D Meyre
Journal:  Diabetologia       Date:  2012-04       Impact factor: 10.122

2.  Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering.

Authors:  Daniel F Berenson; Allison R Weiss; Zhu-Li Wan; Michael A Weiss
Journal:  Ann N Y Acad Sci       Date:  2012-03-13       Impact factor: 5.691

3.  Motivating people to sustain healthy lifestyles using persuasive technology: A pilot study of Korean Americans with prediabetes and type 2 diabetes.

Authors:  Miyong T Kim; Kim Byeng Kim; Tam H Nguyen; Jisook Ko; Jim Zabora; Elizabeth Jacobs; David Levine
Journal:  Patient Educ Couns       Date:  2018-10-29

Review 4.  Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.

Authors:  Bo Ahrén
Journal:  World J Diabetes       Date:  2014-02-15

Review 5.  Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.

Authors:  Ann A Verhaegen; Luc F Van Gaal
Journal:  Curr Obes Rep       Date:  2021-01-05

Review 6.  Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.

Authors:  A A Verhaegen; L F Van Gaal
Journal:  J Endocrinol Invest       Date:  2017-06-28       Impact factor: 4.256

7.  Genetically predicted milk consumption and bone health, ischemic heart disease and type 2 diabetes: a Mendelian randomization study.

Authors:  Q Yang; S L Lin; S L Au Yeung; M K Kwok; L Xu; G M Leung; C M Schooling
Journal:  Eur J Clin Nutr       Date:  2017-02-22       Impact factor: 4.016

8.  Efficacy and safety of insulin lispro protamine suspension as basal supplementation in patients with type 2 diabetes.

Authors:  Dario Giugliano; Katherine Esposito
Journal:  Ther Adv Endocrinol Metab       Date:  2012-06       Impact factor: 3.565

9.  Long-acting basal insulin analogs: latest developments and clinical usefulness.

Authors:  Anastasia N Mavrogiannaki; Ilias N Migdalis
Journal:  Ther Adv Chronic Dis       Date:  2012-11       Impact factor: 5.091

10.  Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death.

Authors:  Jea Young Min; Amber J Hackstadt; Marie R Griffin; Robert A Greevy; Jonathan Chipman; Carlos G Grijalva; Adriana M Hung; Christianne L Roumie
Journal:  Diabetes Obes Metab       Date:  2019-08-29       Impact factor: 6.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.